Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations-Reference-Cited by-同舟云学术

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

Published:2019-12-01 Issue:4 Volume:82 Page:e47-e49
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Wong Alexander,Goldstein Deborah,Mallolas Josep,DeJesus Edwin,Johnson Margaret,Molina Jean-Michel,Pozniak Anton,Rodgers Anthony,Teal Valerie,Hepler Deborah,Kumar Sushma,Sklar Peter,Hanna George J.,Hwang Carey,Badshah Cyrus,Teppler Hedy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference11 articles.

1. Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999–2011;Buchacz;J Antimicrob Chemother.,2015

2. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis;Gupta;Lancet Infect Dis.,2018

3. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe;Frentz;BMC Infect Dis.,2014

4. The global burden of HIV-1 drug resistance in the past 20 years;Zazzi;PeerJ.,2018

5. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects;Anderson;Antivir Ther (Lond).,2015

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry;International Journal of Antimicrobial Agents;2023-03

2. Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance;AIDS Research and Therapy;2023-02-07

3. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022;HIV Medicine;2022-12

4. Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug Resistance;2022-08-23

5. High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen;Infection and Drug Resistance;2022-07